Literature DB >> 10812218

Analysis of varicella vaccine breakthrough rates: implications for the effectiveness of immunisation programmes.

M Brisson1, W J Edmunds, N J Gay, B Law, G De Serres.   

Abstract

The objective of this study was to quantify key parameters describing varicella zoster virus (VZV) vaccine efficacy. To do so a mathematical model was developed to represent breakthrough cases as a function of time after vaccination in vaccine efficacy trials. Efficacy parameter sets were identified by fitting the predicted annual number of breakthrough infections with that observed in three clinical trials chosen to represent the plausible range of vaccine efficacy. Results suggest that varicella vaccination seems to result in a high proportion of individuals who are initially totally protected (97% for the base-case). However, individuals lose full protection relatively rapidly (3% per year for the base-case). Once total protection has waned individuals have a high probability of developing a breakthrough infection if exposed to varicella (73% of the probability in unvaccinated susceptibles for the base-case). Results also highlight that vaccine efficacy parameters should be estimated concurrently to take into account dependencies between parameters.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10812218     DOI: 10.1016/s0264-410x(00)00100-6

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  14 in total

Review 1.  Varicella vaccination--a critical review of the evidence.

Authors:  S A Skull; E E Wang
Journal:  Arch Dis Child       Date:  2001-08       Impact factor: 3.791

2.  Do costs of varicella justify routine infant vaccination? Pharmacoeconomic and clinical considerations.

Authors:  M J Postma; J M Bos; R Welte; R de Groot; W Luytjes; H C Rümke; P Beutels
Journal:  Eur J Health Econ       Date:  2004-02

Review 3.  Economic evaluations of varicella vaccination programmes: a review of the literature.

Authors:  Nancy Thiry; Philippe Beutels; Pierre Van Damme; Eddy Van Doorslaer
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

4.  Epidemiological game-theory dynamics of chickenpox vaccination in the USA and Israel.

Authors:  Jingzhou Liu; Beth F Kochin; Yonas I Tekle; Alison P Galvani
Journal:  J R Soc Interface       Date:  2011-06-01       Impact factor: 4.118

5.  Varicella Vaccination Two-Dose Recommendations: An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI).

Authors:  Ben Tan; Shainoor Ismail
Journal:  Can Commun Dis Rep       Date:  2010-09-20

Review 6.  Primary versus secondary failure after varicella vaccination: implications for interval between 2 doses.

Authors:  Paolo Bonanni; Anne Gershon; Michael Gershon; Andrea Kulcsár; Vassiliki Papaevangelou; Bernard Rentier; Catherine Sadzot-Delvaux; Vytautas Usonis; Timo Vesikari; Catherine Weil-Olivier; Peter de Winter; Peter Wutzler
Journal:  Pediatr Infect Dis J       Date:  2013-07       Impact factor: 2.129

Review 7.  Progress in VZV vaccination? Some concerns.

Authors:  H W Doerr
Journal:  Med Microbiol Immunol       Date:  2013-05-07       Impact factor: 3.402

8.  Varicella vaccination in Europe: are we ready for a universal childhood programme?

Authors:  Nitu Sengupta; Robert Booy; H J Schmitt; Heikki Peltola; Pierre Van-Damme; R Fabian Schumacher; Magda Campins; Carlos Rodrigo; Terho Heikkinen; Jane Seward; Aisha Jumaan; Adam Finn; Per Olcén; Nancy Thiry; Catherine Weil-Olivier; Judith Breuer
Journal:  Eur J Pediatr       Date:  2007-03-03       Impact factor: 3.860

9.  The impact of demographic changes on the epidemiology of herpes zoster: Spain as a case study.

Authors:  Valentina Marziano; Piero Poletti; Giorgio Guzzetta; Marco Ajelli; Piero Manfredi; Stefano Merler
Journal:  Proc Biol Sci       Date:  2015-04-07       Impact factor: 5.349

10.  Perspectives on the impact of varicella immunization on herpes zoster. A model-based evaluation from three European countries.

Authors:  Piero Poletti; Alessia Melegaro; Marco Ajelli; Emanuele Del Fava; Giorgio Guzzetta; Luca Faustini; Giampaolo Scalia Tomba; Pierluigi Lopalco; Caterina Rizzo; Stefano Merler; Piero Manfredi
Journal:  PLoS One       Date:  2013-04-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.